RCC/Renal Cell Carcinoma, Kidney Cancer News Articles

Anti-PD-L1 Combinations Produce Mixed Results in Metastatic RCC

May 30, 2023

Anti-PD-L1-based therapies may improve some outcomes over sunitinib in patients with metastatic renal cell carcinoma, a meta-analysis suggests.

Global Survey Suggests RCC Patients Are Underinformed, Face Obstacles to Care

May 16, 2023

Results of a global survey highlight areas for improvement in the care of patients with renal cell carcinoma.

Cancer Patients With Diabetes May Have Worse Outcomes on ICIs

May 15, 2023

Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.

Triplet Outperforms Doublet in RCC

May 12, 2023

Adding cabozantinib to first-line treatment with ipilimumab plus nivolumab improved progression-free survival in patients with advanced, intermediate- or poor-risk renal cell carcinoma.

Perioperative Outcomes of Cytoreductive Nephrectomy Improving in Metastatic RCC

May 4, 2023

Perioperative outcomes of cytoreductive nephrectomy for metastatic renal cell carcinoma improved from 2005 to 2019.

Blood Type Associated With Immunotherapy Outcomes in RCC

May 3, 2023

Blood type may impact immunotherapy outcomes in patients with metastatic RCC, a study suggests.

Cryoablation of T1a RCC Can Provide Long-Term Disease Control

May 2, 2023

Percutaneous cryoablation of localized T1a RCC provides long-term oncologic control with a low rate of complications, according to researchers.

ALLO-316, a CAR T-Cell Therapy, Shows Activity in Advanced RCC

April 21, 2023

ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.

Belzutifan Plus Cabozantinib Deemed Promising for Advanced RCC

April 10, 2023

Combination treatment with belzutifan and cabozantinib has demonstrated antitumor activity in previously treated, advanced clear cell renal cell carcinoma.

Avelumab Plus Cabozantinib Appears Safe, Active in Metastatic Clear Cell RCC

April 6, 2023

Avelumab plus cabozantinib has shown preliminary clinical activity and an acceptable safety profile in metastatic clear cell RCC, according to researchers.

Researchers Identify Genetic Correlations Across Cancer Types

April 5, 2023

Researchers have identified 15 novel loci associated with cancer and discovered genetic correlations across different cancer types.

Keytruda Granted Full Approval for Advanced MSI-H or dMMR Solid Tumors

March 31, 2023

The conversion from accelerated approval to regular approval was based on data from the KEYNOTE-158 trial, the KEYNOTE-164 trial, and the KEYNOTE-051 trial.

Positive Surgical Margins Linked to Worse RCC Recurrence, Survival Rates

March 21, 2023

Findings may inform treatment decisions after nephrectomy with positive surgical margins.

Fat Loss Portends Worse Prognosis in ICI-Treated Metastatic Clear Cell RCC

March 17, 2023

Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.

Partial Cytoreductive Nephrectomy Still Offers Survival Edge in Metastatic RCC

March 16, 2023

Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.

Benefits Persist for Lenvatinib Plus Pembrolizumab in Renal Cell Cancer

March 15, 2023

Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.

RCC Stratification System May Need to Be Refined, Data Suggest

March 14, 2023

Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.